Cannabis and Post-Herpetic Neuralgia
What the evidence actually says about using cannabis to treat the lingering nerve pain that follows a shingles outbreak.
Post-herpetic neuralgia is brutal neuropathic pain, and standard treatments often only take the edge off. Cannabis is sometimes pitched as a miracle fix — it isn't. The strongest evidence comes from a handful of small trials, mostly on neuropathic pain generally, not PHN specifically. Some patients get real relief; others get side effects and no benefit. If gabapentinoids, TCAs, and topical lidocaine have failed you, cannabis is a reasonable thing to discuss with a doctor — not a first-line cure.
Plain-language summary
Post-herpetic neuralgia (PHN) is nerve pain that lingers after a shingles rash heals — sometimes for months or years. It's classified as neuropathic pain, meaning the nerves themselves are damaged or misfiring. Standard treatments (gabapentin, pregabalin, tricyclic antidepressants, topical lidocaine, topical capsaicin) help some people but rarely eliminate the pain [1].
Cannabis is frequently discussed as an alternative. The honest picture: there is moderate evidence that cannabinoids can reduce chronic neuropathic pain in general Weak / limited, but no large, well-designed trial has tested cannabis specifically in PHN. So most of what you'll read online extrapolates from related conditions like HIV neuropathy, diabetic neuropathy, or multiple sclerosis pain.
This article is not medical advice. PHN is a real medical condition that interacts with other drugs (especially gabapentinoids and opioids) and with age-related health issues. Talk to a clinician before starting, stopping, or combining anything.
What probably works
Honestly: nothing in cannabis has strong evidence specifically for PHN. The closest we get is general chronic neuropathic pain.
- Oral or oromucosal THC:CBD (nabiximols / Sativex) has been shown in randomized trials to modestly reduce chronic neuropathic pain of various causes, including a small subset with PHN-like presentations Weak / limited[2][3]. Effect sizes are real but modest — typically a 1–2 point reduction on a 10-point pain scale versus placebo.
- Inhaled THC-dominant cannabis has reduced neuropathic pain in small short-duration trials in HIV neuropathy and mixed neuropathy populations Weak / limited[4][5]. Whether this generalizes to PHN is unproven but plausible given shared mechanisms.
That's it for the "probably works" tier, and even this is on shaky ground. The National Academies 2017 review classified evidence for cannabis in chronic pain as "substantial," but specifically flagged that PHN was underrepresented in trials [1].
What might work
- CBD-dominant products for PHN: biologically plausible (CBD modulates TRPV1 and inflammatory signaling), but human trial data in PHN is essentially absent No data. Don't trust marketing claims here.
- Topical cannabinoid creams applied to the affected dermatome: small case series and one open-label study suggest possible benefit for localized neuropathic pain and itch Anecdote[6]. No placebo-controlled PHN trial exists.
- Cannabis for PHN-associated insomnia and mood: chronic pain disrupts sleep and triggers depression; THC and CBD have weak evidence for sleep in chronic pain populations generally Weak / limited. This is an indirect benefit, not a treatment of the nerve pain itself.
- CBD + standard care as an add-on: theoretically interesting because CBD has fewer psychoactive side effects than THC, but no PHN-specific data No data.
What doesn't work or has weak evidence
- "Indica strains are better for nerve pain." Folklore. The indica/sativa labels don't reliably predict chemistry or clinical effect Disputed[7]. See Indica vs Sativa.
- Specific cultivars marketed as "PHN strains." No clinical data supports any specific cultivar for PHN. Dispensary recommendations here are marketing.
- CBD isolate gummies curing PHN. No evidence No data. CBD isolate at typical consumer doses (10–25 mg) is well below doses used in any neuropathic pain trial (often 200–600 mg/day of pharmaceutical-grade CBD).
- Cannabis shortening or preventing PHN after shingles. No evidence cannabis affects the underlying viral or nerve-damage process No data. Antivirals taken within 72 hours of shingles onset, and the shingles vaccine (Shingrix), are the interventions that actually reduce PHN risk [8].
What we don't know
- Whether cannabis works better, worse, or the same as gabapentin or pregabalin in PHN specifically — no head-to-head trial exists.
- Optimal THC:CBD ratio for neuropathic pain.
- Whether long-term cannabis use in older adults (the typical PHN patient is over 60) causes cognitive or cardiovascular harm beyond what's seen in younger users — this is an active concern Weak / limited[9].
- Whether topical cannabinoids reach therapeutic concentrations in damaged peripheral nerves.
- Drug interactions between CBD and the medications most PHN patients are already taking (amitriptyline, gabapentin, opioids). CBD inhibits several cytochrome P450 enzymes and can raise blood levels of other drugs Strong evidence[10].
Comparison with standard treatments
First-line treatments for PHN have stronger and more specific evidence than cannabis:
- Gabapentin / pregabalin: multiple RCTs, ~30–50% pain reduction in roughly a third of patients Strong evidence[1][11].
- Tricyclic antidepressants (nortriptyline, amitriptyline): long-established, similar effect size Strong evidence[11].
- Topical lidocaine 5% patches: effective for localized PHN with minimal systemic side effects Strong evidence[11].
- Topical capsaicin 8% patch: a single application can give weeks of relief Strong evidence[11].
- Cannabis (THC:CBD): weak-to-moderate evidence in general neuropathic pain, no PHN-specific trial Weak / limited.
Realistic positioning: cannabis is not a replacement for first-line therapy. It's a reasonable add-on or alternative to consider when first-line treatments have failed or caused intolerable side effects — the same niche it occupies in most chronic pain guidelines [1].
Risks and practical considerations
PHN patients tend to be older, often on multiple medications, and frequently have cardiovascular comorbidities. Specific risks:
- Cognitive side effects from THC, including confusion and falls — particularly concerning in older adults Strong evidence[9].
- Sedation stacking with gabapentin, pregabalin, opioids, or TCAs. Combinations can dangerously suppress alertness.
- Cardiovascular effects of THC (transient tachycardia, blood pressure changes) — relevant if you have coronary artery disease Strong evidence[9].
- Drug interactions: CBD raises levels of several common drugs via CYP inhibition Strong evidence[10].
- Cannabinoid hyperemesis with chronic heavy use Strong evidence.
- Dependence and withdrawal with regular daily use Strong evidence.
- Regulatory and product-quality issues: unregulated CBD products are frequently mislabeled for potency and contaminants Strong evidence[12].
If you're going to try cannabis for PHN, the harm-reduction approach is: tell your doctor, start very low (e.g., 2.5 mg THC or a balanced THC:CBD preparation), titrate slowly, avoid combining with alcohol or new sedatives, and reassess honestly after 2–4 weeks whether it's actually helping.
This article is not medical advice. It's a summary of published evidence as of writing. Decisions about treating PHN should be made with a clinician who knows your full medical history.
Sources
- Book National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press.
- Peer-reviewed Nurmikko, T. J., et al. (2007). Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain, 133(1-3), 210-220.
- Peer-reviewed Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, 3(3), CD012182.
- Peer-reviewed Abrams, D. I., et al. (2007). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology, 68(7), 515-521.
- Peer-reviewed Wilsey, B., et al. (2013). Low-dose vaporized cannabis significantly improves neuropathic pain. The Journal of Pain, 14(2), 136-148.
- Peer-reviewed Phan, N. Q., Siepmann, D., Gralow, I., & Ständer, S. (2010). Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. Journal der Deutschen Dermatologischen Gesellschaft, 8(2), 88-91.
- Peer-reviewed Smith, S. C., & Wagner, M. S. (2014). Clinical endocannabinoid deficiency (CECD) revisited; and Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa Versus Cannabis indica Debate. Cannabis and Cannabinoid Research, 1(1), 44-46.
- Government Centers for Disease Control and Prevention. Shingles (Herpes Zoster): Clinical Overview and Prevention. CDC.gov. ↗
- Peer-reviewed Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219-2227.
- Peer-reviewed Brown, J. D., & Winterstein, A. G. (2019). Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine, 8(7), 989.
- Peer-reviewed Finnerup, N. B., et al. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet Neurology, 14(2), 162-173.
- Peer-reviewed Bonn-Miller, M. O., et al. (2017). Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA, 318(17), 1708-1709.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Neuropathic Pain — What the evidence actually says about using cannabis to treat nerve pain, by condition and...